The growth-inhibition effect of tamoxifen in the combination chemotherapeutics on the human cholangiocarcinoma cell line QBC939

In the individual application of adriamycin, mitomycin, vindesine and their combined application with tamoxifen for the pre-treatment of the human cholangiocarcinoma cell line QBC939, QBC939 was determined by MTT assay to investigate the inhibitive effect and its initial mechanism of TAM on cell growth. Growth cycle and apoptosis of each group were determined by flow cytometry. Concentration of ADM in QBC939 was detected by flow cytometry. The levels of their P-glycoprotein were detected by immunohistochemistry. The mRNA and protein levels of apoptotic-associated genes Bcl-2 and Bax were determined by western blot and real-time PCR. The inhibitive rates of adriamycin, mitomycin, vindesine to QBC939 and the apoptosis rates of QBC939 were enhanced after the pre-treatment of tamoxifen. Influence of tamoxifen in their growth cycle was not so obvious except vindesine group because of the increasing cell numbers of G2/M phase in which cells may be blocked. The contents of adriamycin in cells rose after the pre-treatment of tamoxifen. Expression level of the multi-drug resistant protein on cell surface was shown as (+). Furthermore, real-time PCR and Western blot analysis revealed an upregulation of Bcl-2 and a downregulation of Bax in QBC939 after the pre-treatment of tamoxifen. Therefore, tamoxifen may have the ability to enhance the relative sensitivity of QBC939 to chemotherapeutics.

[1]  T. Linné,et al.  Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  G. Hooiveld,et al.  Function and regulation of ATP-binding cassette transport proteins involved in hepatobiliary transport. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[3]  D. Meijer,et al.  Function and regulation of ATP-binding cassette transport proteins involved in hepatobiliary transport (vol 12, pg 13, 2000) , 2001 .

[4]  T. Todoroki,et al.  Treatment strategy for patients with middle and lower third bile duct cancer , 2001, The British journal of surgery.

[5]  P. Magee,et al.  Protein bound carboxyl-methyl ester as a precursor of methanol formation during oxidation of dimethylnitrosamine in vitro. , 1977, Cancer letters.

[6]  T. Bowling,et al.  A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma. , 1996, Gut.

[7]  P. Kortan,et al.  Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage. , 1996, Gastrointestinal endoscopy.

[8]  T. Todoroki.  Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery. , 2000, Hepato-Gastroenterology.

[9]  S. Mandlekar,et al.  Mechanisms of tamoxifen-induced apoptosis , 2001, Apoptosis.

[10]  J. Koropatnick,et al.  Enhancement of cytotoxicity of natural product drugs against multidrug resistant variant cell lines of human head and neck squamous cell carcinoma and breast carcinoma by tesmilifene. , 2009, Cancer letters.

[11]  S. Okushiba,et al.  Effectiveness of Radiation Therapy After Surgery for Hilar Cholangiocarcinoma , 2005, Surgery Today.

[12]  T. Takada,et al.  Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? , 2002, Cancer.

[13]  Alphonse E. Sirica,et al.  Cholangiocarcinoma: Molecular targeting strategies for chemoprevention and therapy , 2005, Hepatology.

[14]  T. Ponchon,et al.  Predictive factors for survival of patients with inoperable malignant distal biliary strictures: a practical management guideline , 1998, Gut.

[15]  I. Brown,et al.  Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells , 2004, Breast Cancer Research.

[16]  H. El‐Serag,et al.  The epidemiology of cholangiocarcinoma. , 2004, Seminars in liver disease.

[17]  Thierry Ponchon,et al.  Plastic or metal stents for malignant stricture of the common bile duct? Results of a randomized prospective study. , 2003, Gastrointestinal endoscopy.

[18]  F. Martin,et al.  The multiple applications of tamoxifen: an example pointing to SERM modulation being the aspirin of the 21st century. , 2008, Medical science monitor : international medical journal of experimental and clinical research.

[19]  G. Gores,et al.  Erratum: Cholangiocarcinoma (Gastroenterology (2005) 128 (1655-1667)) , 2005 .

[20]  M. Ewertz,et al.  Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: A randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C) , 2008, Acta oncologica.

[21]  J. Tobias.  Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women. , 2004, The international journal of biochemistry & cell biology.

[22]  P. Qiu,et al.  Antiproliferation and apoptosis induced by tamoxifen in human bile duct carcinoma QBC939 cells via upregulated p53 expression. , 2009, Biochemical and biophysical research communications.

[23]  T. Matsunaga,et al.  Magnetic cell separation using nano‐sized bacterial magnetic particles with reconstructed magnetosome membrane , 2008, Biotechnology and bioengineering.

[24]  S. Neidle,et al.  Acquired cellular resistance to flavopiridol in a human colon carcinoma cell line involves up-regulation of the telomerase catalytic subunit and telomere elongation. Sensitivity of resistant cells to combination treatment with a telomerase inhibitor. , 2003, Molecular pharmacology.

[25]  E. Jaurrieta,et al.  Changing strategies in diagnosis and management of hilar cholangiocarcinoma , 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[26]  U. Brinkmann,et al.  ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. , 2001, Pharmacogenomics.

[27]  James B. Mitchell,et al.  Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. , 1987, Cancer research.

[28]  H. Hur,et al.  Intrahepatic cholangiocarcinoma associated with intrahepatic duct stones. , 2009, Asian journal of surgery.

[29]  S. Takao,et al.  Length and quality of survival following external beam radiotherapy combined with expandable metallic stent for unresectable hilar cholangiocarcinoma , 2000, Journal of surgical oncology.

[30]  D. Smith,et al.  Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer , 2005, British Journal of Cancer.

[31]  D. Grainger,et al.  Tamoxifen: Teaching an old drug new tricks? , 1996, Nature Medicine.

[32]  G. Gores,et al.  Biliary tract cancers. , 1999, The New England journal of medicine.

[33]  K. Lillemoe,et al.  Perihilar Cholangiocarcinoma Postoperative Radiotherapy Does Not Improve Survival , 1995, Annals of surgery.

[34]  M. Gonen,et al.  Staging, Resectability, and Outcome in 225 Patients With Hilar Cholangiocarcinoma , 2001, Annals of surgery.